Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prednisolone Streuli is an approved synthetic glucocorticoid medication developed and marketed by Streuli Pharma AG. The active ingredient, prednisolone, is a synthetic corticosteroid that functions as an agonist of the intracellular glucocorticoid receptor. Upon binding, the receptor-ligand complex translocates to the cell nucleus, where it interacts with specific DNA sequences to modulate gene expression. This action results in potent anti-inflammatory, immunosuppressive, antiallergic, and antiproliferative effects. Prednisolone Streuli is indicated for the systemic treatment of various inflammatory and autoimmune conditions, as well as other steroid-responsive disorders requiring corticosteroid therapy. It is available in oral tablet formulations of various strengths.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Prednisolone Streuli.